secwatch / observer

8-K/A filed August 23, 2023, 7:59 PM ET ticker YHC CIK 0001843165

leadership confidence high sentiment neutral materiality 0.60

Appoints Jay Dhaliwal to Board; Launches Preliminary Naked Short Selling Investigation

LQR House Inc.

Jay Dhaliwal appointed to Board effective Aug 21, 2023, increasing board from 7 to 8 members.
Dhaliwal is independent; current CEO of Global Health Clinics and interim CEO of Ravenquest Biomed; serves on several public company boards.
LQR House will conduct preliminary investigation into possible naked short selling and manipulation of its common shares on NASDAQ.
Company enters standard indemnity and director agreements, and restricted stock unit award agreement with Dhaliwal.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jatinder (Jay) Dhaliwal

member of the Board of Directors

YHC · LQR House Inc.

Effective: 2023-08-21
Filed: August 23, 2023, 7:59 PM ET

On August 21, 2023, the Board appointed Jatinder (Jay) Dhaliwal as a member of the Board of Directors (the “Board”), effective August 21, 2023, increasing the number of directors from seven (7) to eight (8).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jatinder (Jay) Dhaliwal was appointed as member of the Board of Directors at LQR House Inc..

Action: appointed
Role: member of the Board of Directors

Exact text from the filing

On August 21, 2023, the Board appointed Jatinder (Jay) Dhaliwal as a member of the Board of Directors (the “Board”), effective August 21, 2023, increasing the number of directors from seven (7) to eight (8).

View on SEC.gov

LQR House Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-070186

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.